Lumen

1 known investors

Lumen develops orally-delivered biologic drugs using genetically engineered spirulina algae, which expresses therapeutic proteins such as enzymes, antibodies, and cytokines that are spray-dried into shelf-stable powders and capsules. Its pipeline targets conditions including weight loss, C. difficile, Crohn's disease, ulcerative colitis, and respiratory infections.